Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin

被引:146
作者
Basu, Samik [1 ]
Golovina, Tatiana [1 ]
Mikheeva, Tatiana [1 ]
June, Carl H. [1 ]
Riley, James L. [1 ]
机构
[1] Univ Penn, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Sch Med, Philadelphia, PA 19104 USA
关键词
D O I
10.4049/jimmunol.180.9.5794
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Addition of rapamycin to cultures of expanding natural If CD4(+)CD25(+)Foxp3(+) T regulatory cells (Tregs) helps maintain their suppressive activity, but the underlying mechanism is unclear. Pim 2 is a serine/threonine kinase that can confer rapamycin resistance. Unexectedly, pim 2 was found to be constitutively expressed in freshly isolated, resting Tregs, but not in CD4(+) CD25(-) T effector T cells induced pim 2 expression and conferred preferential expansion in the presence of rapamycin, indicating that Foxp3 can regulate pim 2 expression. Finally, we determined there is a positive correlation between Treg expansion and Toxp3 expression in the presence of rapamycin. Together, these results indicate that Tregs are programmed to be resistant to rapamycin, providing further rationale for why this immunosuppressive drug should be used in conjunction with expanded Tregs.
引用
收藏
页码:5794 / 5798
页数:5
相关论文
共 25 条
  • [1] Expression of human pim family genes is selectively up-regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation
    Aho, TLT
    Lund, RJ
    Ylikoski, EK
    Matikainen, S
    Lahesmaa, R
    Koskinen, PJ
    [J]. IMMUNOLOGY, 2005, 116 (01) : 82 - 88
  • [2] The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs
    Allan, SE
    Passerini, L
    Bacchetta, R
    Crellin, N
    Dai, MY
    Orban, PC
    Ziegler, SF
    Roncarolo, MG
    Levings, MK
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (11) : 3276 - 3284
  • [3] Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc
    Allen, JD
    Verhoeven, E
    Domen, J
    vanderValk, M
    Berns, A
    [J]. ONCOGENE, 1997, 15 (10) : 1133 - 1141
  • [4] Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
    Battaglia, M
    Stabilini, A
    Roncarolo, MG
    [J]. BLOOD, 2005, 105 (12) : 4743 - 4748
  • [5] Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients
    Battaglia, Manuela
    Stabilini, Angela
    Migliavacca, Barbara
    Horejs-Hoeck, Jutta
    Kaupper, Thomas
    Roncarolo, Maria-Grazia
    [J]. JOURNAL OF IMMUNOLOGY, 2006, 177 (12) : 8338 - 8347
  • [6] Regulatory T-cell therapy: is it ready for the clinic?
    Bluestone, JA
    [J]. NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) : 343 - 349
  • [7] B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs
    Chemnitz, Jens M.
    Lanfranco, Anthony R.
    Braunstein, Inbal
    Riley, James L.
    [J]. JOURNAL OF IMMUNOLOGY, 2006, 176 (11) : 6603 - 6614
  • [8] Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells
    Coenen, JJA
    Koenen, HJPM
    van Rijssen, E
    Hilbrands, LB
    Joosten, I
    [J]. BLOOD, 2006, 107 (03) : 1018 - 1023
  • [9] The Pim kinases control rapamycin-resistant T cell survival and activation
    Fox, CJ
    Hammerman, PS
    Thompson, CB
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (02) : 259 - 266
  • [10] The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor
    Fox, CJ
    Hammerman, PS
    Cinalli, RM
    Master, SR
    Chodosh, LA
    Thompson, CB
    [J]. GENES & DEVELOPMENT, 2003, 17 (15) : 1841 - 1854